Tyrosine News and Research

RSS

Researchers propose alternative treatment to target lymphoma signaling at its root

Non-Hodgkin lymphomas are cancers that affect white blood cells of the immune system called B-lymphocytes or B cells. Like cells in all cancers, the B cells begin to grow out of control, creating tumors in the lymph nodes, spleen or other tissues. In 2010 alone, it was estimated that non-Hodgkin lymphomas caused 210,000 deaths worldwide.

22 Mar 2018

University of Akron professor receives NSF grant for research that supports anti-cancer therapeutics

Dr. Adam W. Smith, assistant professor in the Department of Chemistry, has won a CAREER award from the National Science Foundation. The title of the award is "Lipid Regulation of Receptor Tyrosine Kinases" and provides $650,000 of funding for research.

15 Mar 2018

Study finds novel therapeutic strategy that preserves neuromuscular synapses in ALS mouse model

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, causes lethal respiratory paralysis within several years of diagnosis. There are no effective treatments to slow or halt this devastating disease.

21 Feb 2018

Researchers uncover how excess calcium may influence development of Parkinson’s disease

Researchers have found that excess levels of calcium in brain cells may lead to the formation of toxic clusters that are the hallmark of Parkinson's disease.

19 Feb 2018

Research project succeeds in palliating kidney disease caused by diabetes in mice

Diabetes has become a major health problem worldwide; some estimates suggest that in twenty years' time there will be around 600 million diabetics. The disease is caused by impaired insulin secretion, which in turn hinders cell glucose uptake; as a result, sugar levels in the bloodstream remain excessively high.

8 Feb 2018

Researchers use innovative method to screen kinases for cancer drug's effectiveness

In recent years, a powerful suite of drugs known as kinase inhibitors have been developed to treat cancer and other diseases. Primary targets of such drugs include a family of receptor tyrosine kinases (RTKs) which protrude from cell surfaces like antennae and can activate cancer-related pathways in virtually all types of cancer when signaling molecules bind with them.

5 Feb 2018

Scientists synthesize new multifunctional compound that has anti-tumor properties

A research team of the UNN Faculty of Chemistry led by Professor Alexei Fedorov has developed and synthesized a new multifunctional compound that possesses anti-tumor properties that are due to several independent effects.

2 Feb 2018

Leading medical societies update molecular testing guideline for lung cancer

Rapid advancements in the molecular diagnostic testing of lung cancer have led to new treatments and greater hope for patients battling lung cancer, the most common cause of cancer death worldwide.

24 Jan 2018

Experts issue updated guidelines for molecular diagnostic testing of patients with lung cancer

A panel of leading experts in molecular pathology has issued new recommendations and updates to guidelines for molecular diagnostic testing of patients with lung cancer.

23 Jan 2018

Study reveals a loophole in treatment of chronic lymphocytic leukemia

A team of researchers in Italy and Austria has determined that a drug approved to treat chronic lymphocytic leukemia (CLL) may be less effective in a particular subset of patients.

4 Jan 2018

Novartis announces FDA approval of its first and only CML therapy with TFR data in product label

Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of Treatment-free Remission (TFR) data in the Tasigna® (nilotinib) US product label.

26 Dec 2017

Researchers identify novel mechanism that protects from brain tumor

A group of researchers at the Spanish National Cancer Research Centre have identified a protein called RanBP6 as a new regulator of EGFR. In a paper published in Nature Communications they show how silencing of RanBP6 promoted glioma growth, by upregulating EGFR expression.

18 Dec 2017

Study provides new insights into development of Sonic Hedgehog medulloblastoma

Medulloblastoma is the most common type of solid brain tumor in children. Current treatments offer limited success and may leave patients with severe neurological side effects, including psychiatric disorders, growth retardation and cognitive impairment.

13 Dec 2017

Combination of chemotherapy and targeted drug improves response in younger CLL patients

Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with chemotherapy alone, according to an investigator-initiated multi-center phase II clinical trial.

11 Dec 2017

UNIGE scientists unravel key role played by the liver in onset of type-2 diabetes

Affecting as many as 650 million people worldwide, obesity has become one of the most serious global health issues. Among its detrimental effects, it increases the risk of developing metabolic conditions, and primarily type-2 diabetes.

28 Nov 2017

Study: Alectinib 600 mg more effective than standard therapy in Asian ALK positive NSCLC patients

A subanalysis of the phase III ALEX study has shown that alectinib 600 mg twice daily is more effective than standard of care crizotinib in Asian patients with anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC), researchers report at the ESMO Asia 2017 Congress.

20 Nov 2017

Osimertinib provides progression-free survival benefit to Asian patients with EGFR-mutated NSCLC

Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the FLAURA trial presented at the ESMO Asia 2017 Congress, sumultaneously published in The New England Journal of Medicine.

20 Nov 2017

Mount Sinai researchers identify new therapeutic target for ER+ breast cancer

Researchers at the Icahn School of Medicine at Mount Sinai have identified a protein that can be targeted to suppress growth of a common type of breast cancer known as "estrogen receptor positive" (ER+), including ER+ cancers that are resistant to standard treatments.

17 Nov 2017

Elevated levels of chronic stress hormones may promote EGFR inhibitor resistance in NSCLC patients

Elevated levels of chronic stress hormones, such as those produced by psychological distress, may promote resistance to drugs commonly used to treat lung cancer patients with EGFR mutations, according to new research from The University of Texas MD Anderson Cancer Center.

9 Nov 2017

Researchers use gold nanoshells to effectively release cancer drugs inside tumors

Researchers investigating ways to deliver high doses of cancer-killing drugs inside tumors have shown they can use a laser and light-activated gold nanoparticles to remotely trigger the release of approved cancer drugs inside cancer cells in laboratory cultures.

8 Nov 2017